Devonian Health Group Inc
XTSX:GSD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
S
|
SI Holdings Plc
TSE:7070
|
JP |
Devonian Health Group Inc
Other
Devonian Health Group Inc
Other Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Devonian Health Group Inc
XTSX:GSD
|
Other
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Other
-$105m
|
CAGR 3-Years
9%
|
CAGR 5-Years
0%
|
CAGR 10-Years
13%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Other
-CA$21.3m
|
CAGR 3-Years
10%
|
CAGR 5-Years
-119%
|
CAGR 10-Years
-22%
|
|
|
Cronos Group Inc
TSX:CRON
|
Other
-$10.2m
|
CAGR 3-Years
-52%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-74%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Other
-$522k
|
CAGR 3-Years
-8%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Other
-CA$6.9m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-49%
|
|
Devonian Health Group Inc
Glance View
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Pointe-Claire, Quebec. The company went IPO on 2014-09-09. The Company’s flagship product, Thykamine, the pharmaceutical product issued from its SUPREX platform, is a product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies, as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a Phase II clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis. The firm is also involved in the development of cosmeceutical products.
